Argenx Se (ARGX) Net Income towards Common Stockholders (QoQ) (2017 - 2026)
Argenx Se (ARGX) Net Income towards Common Stockholders (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.96% |
| Mar 31, 2026 | -31.33% |
| Dec 31, 2025 | 54.81% |
| Sep 30, 2025 | 40.31% |
| Jun 30, 2025 | 45.18% |
| Mar 31, 2025 | -78.17% |
| Dec 31, 2024 | 746.91% |
| Sep 30, 2024 | 214.49% |
| Jun 30, 2024 | 147.19% |
| Mar 31, 2024 | 37.89% |
| Dec 31, 2023 | -36.52% |
| Sep 30, 2023 | 23.02% |
| Jun 30, 2023 | -426.86% |
| Mar 31, 2023 | 174.77% |
| Dec 31, 2022 | -116.43% |
| Sep 30, 2022 | -64.56% |
| Jun 30, 2022 | 391.89% |
| Mar 31, 2022 | 4.47% |
| Dec 31, 2021 | -1.80% |
| Sep 30, 2021 | -1,127.60% |